Press Releases


New $35 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-19 Crisis in U.S.

April 7, 2020

Tags |  Product

Insulin savings available for people with commercial insurance and the uninsured by calling (833) 808-1234 INDIANAPOLIS , April 7, 2020 /PRNewswire/ -- In response to the crisis caused by COVID-19, Eli Lilly and Company (NYSE: LLY) is introducing the Lilly Insulin Value Program, allowing anyone




Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

March 30, 2020

Tags |  Product

-- Taltz is the first and only IL-17A antagonist approved to treat this population -- INDIANAPOLIS , March 30, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for




Updates from Lilly about insulin supply and affordability

March 24, 2020

Tags |  Product

INDIANAPOLIS , March 24, 2020 /PRNewswire/ -- To keep the diabetes community informed about important developments from the COVID-19 crisis, Eli Lilly and Company (NYSE: LLY) today is providing updates related to insulin supply and affordability: As we announced on March 3 , Lilly does not




US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes

March 20, 2020

Tags |  Product

RIDGEFIELD, Conn. and INDIANAPOLIS, March 20, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has issued a complete response letter for the supplemental New Drug Application (sNDA) of the investigational medicine empagliflozin 2.5 mg as an adjunct to insulin for adults with type 1




Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata

March 16, 2020

Tags |  Product

Recognition reinforces baricitinib's potential to be the first FDA-approved medicine for individuals living with alopecia areata INDIANAPOLIS , March 16, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S.




US FDA grants Fast Track designation to Jardiance® for the treatment of chronic kidney disease

March 12, 2020

Tags |  Product

-- FDA Fast Track designation is for the investigation of potential new therapies that treat serious conditions and fulfill an unmet medical need RIDGEFIELD, Conn. and INDIANAPOLIS, March 12, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the




Lilly to Participate in New Model Designed to Make Insulins More Affordable for Seniors in Medicare Part D

March 11, 2020

Tags |  Product

Participation Adds to Lilly's Suite of Affordability Solutions INDIANAPOLIS , March 11, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) is proud to announce its planned participation in the new Part D Senior Savings Model, announced today by the Centers for Medicare & Medicaid Services




U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis

March 2, 2020

Tags |  Product

NEW YORK and INDIANAPOLIS , March 2, 2020 /PRNewswire/ --  Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for tanezumab 2.5 mg administered subcutaneously (SC),




Eli Lilly and Company Statement on ICER Final Report for Acute Treatments for Migraine: Effectiveness and Value

February 28, 2020

Tags |  Product

INDIANAPOLIS, February 28, 2020 – Eli Lilly and Company shared the following statement in response to the Institute for Clinical and Economic Review (ICER) Final Report on Acute Treatments for Migraine: Effectiveness and Value. Lilly appreciates the recognition the ICER report brings to the need




FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (ramucirumab) as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

February 26, 2020

Tags |  Product

Regulatory submission based on the positive Phase 3 RELAY study of CYRAMZA in combination with erlotinib for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating EGFR mutations INDIANAPOLIS , Feb. 26, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: